Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

Autor: Christof Scheid, Pieter Sonneveld, Ingo G.H. Schmidt-Wolf, Bronno van der Holt, Laila el Jarari, Uta Bertsch, Hans Salwender, Sonja Zweegman, Igor Wolfgang Blau, Edo Vellenga, Katja Weisel, Michael Pfreundschuh, Kon-Siong Jie, Kai Neben, Helgi van de Velde, Ulrich Duehrsen, M. Ron Schaafsma, Walter Lindemann, Marie José Kersten, Norma Peter, Mathias Hänel, Sandra Croockewit, Hans Martin, Shulamiet Wittebol, Gerard MJ Bos, Marinus van Marwijk-Kooy, Pierre Wijermans, Hartmut Goldschmidt, Henk M. Lokhorst

Publikováno v: Haematologica, Vol 99, Iss 1 (2014)

Renal impairment is frequent in patients with multiple myeloma and is correlated with an inferior prognosis. This analysis evaluates the prognostic role of renal impairment in patients with myeloma treated with bortezomib before and after autologous

Externí odkaz: https://doaj.org/article/f8e3a1869ee04ce7b7ebbc39988ad088

Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial

Autor: Eline M. P. Cremers, Saskia K. Klein, Petra Muus, Marian Stevens-Kroef, Georgine E. de Greef, Theresia M. Westers, Canan Alhan, Daniel Olde Weghuis, Pierre W. Wijermans, Sonia M Cunha, Najat ElIdrissi-Zaynoun, M Ron Schaafsma, Edo Vellenga, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Bert A. van der Reijden, Dana A. Chitu, Heleen Visser-Wisselaar, Joop H. Jansen

Publikováno v: Genes, Chromosomes and Cancer. 56:524-534

Karyotyping is considered as the gold standard in the genetic subclassification of myelodysplastic syndrome (MDS). Oligo/SNP-based genomic array profiling is a high-resolution tool that also enables genome wide analysis. We compared karyotyping with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f4b0464314cf046abda92350ec5abc02
https://doi.org/10.1002/gcc.22455

Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial

Autor: Sandra Croockewit, Pieter Sonneveld, Kazem Nasserinejad, Paula F. Ypma, Sonja Zweegman, Esther G. M. de Waal, Annemieke Broijl, Monique C. Minnema, Harry R. Koene, Ka Lung Wu, Marie José Kersten, Gerard M. J. Bos, Stefan Schönland, M Ron Schaafsma, Bouke P. C. Hazenberg, Lidwien Tick, Ute Hegenbart, Philip Vlummens, Nicolaus Kröger

Publikováno v: Haematologica
Haematologica-the Hematology Journal, 104(11), 2274-2282. Ferrata Storti Foundation
Minnema, M C, Nasserinejad, K, Hazenberg, B, Hegenbart, U, Vlummens, P, Ypma, P F, Kröger, N, Wu, K L, Kersten, M J, Schaafsma, M R, Croockewit, S, de Waal, E, Zweegman, S, Tick, L, Broijl, A, Koene, H, Bos, G, Sonneveld, P & Schönland, S 2019, ' Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: Results of the multicenter HOVON 104 trial ', Haematologica, vol. 104, no. 11, pp. 2274-2282 . https://doi.org/10.3324/haematol.2018.213900
Haematologica, 104(11), 2274-2282. Ferrata Storti Foundation
Haematologica, 104(11), 2274. Ferrata Storti Foundation
Haematologica, 104(11), 2274-2282. FERRATA STORTI FOUNDATION
Haematologica, 104, 11, pp. 2274-2282
Haematologica, 104, 2274-2282
HAEMATOLOGICA

This prospective, multicenter, phase II study investigated the use of four cycles of bortezomib-dexamethasone induction treatment, followed by high-dose melphalan and autologous stem cell transplantation (SCT) in patients with newly diagnosed light c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24b31ee17d8ab61f75226a7615039d08
https://pubmed.ncbi.nlm.nih.gov/30923094

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

Autor: Michael Pfreundschuh, Marinus van Marwijk-Kooy, Mathias Hänel, Hartmut Goldschmidt, Kai Neben, M Ron Schaafsma, Walter Lindemann, Ingo G.H. Schmidt-Wolf, Gerard M. J. Bos, Uta Bertsch, Christof Scheid, Norma Peter, Pieter Sonneveld, Sonja Zweegman, Henk M. Lokhorst, Igor Wolfgang Blau, Katja Weisel, Laila el Jarari, Hans Martin, Helgi van de Velde, Edo Vellenga, Kon-Siong G. Jie, Pierre W. Wijermans, Marie José Kersten, Shulamiet Wittebol, Ulrich Duehrsen, Hans Salwender, Sandra Croockewit, Bronno van der Holt

Publikováno v: Haematologica, 99(1), 148-154. Ferrata Storti Foundation
Scheid, C, Sonneveld, P, Schmidt-Wolf, I G H, van der Holt, B, el Jarari, L, Bertsch, U, Salwender, H, Zweegman, S, Blau, I W, Vellenga, E, Weisel, K, Pfreundschuh, M, Jie, K S, Neben, K, van der Velde, H, Duehrsen, U, Schaafsma, M R, Lindemann, W, Kersten, M J, Peter, N, Hanel, M, Croockewit, S, Martin, H, Wittebol, S, Bos, G M J, van Marwijk-Kooy, M, Wijermans, P, Goldschmidt, H & Lokhorst, H M 2014, ' Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial ', Haematologica, vol. 99, no. 1, pp. 148-154 . https://doi.org/10.3324/haematol.2013.087585
Haematologica, 99(1), 148-154. FERRATA STORTI FOUNDATION
Haematologica-the Hematology Journal, 99(1), 148-54. Ferrata Storti Foundation
Haematologica, 99, 1, pp. 148-54
Haematologica, 99, 148-54

Contains fulltext : 137125.pdf (Publisher’s version ) (Open Access) Renal impairment is frequent in patients with multiple myeloma and is correlated with an inferior prognosis. This analysis evaluates the prognostic role of renal impairment in pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33c432361eff36235aa2c2728d66e436
https://pure.eur.nl/en/publications/18f6639a-7e8f-472b-a72c-11bb195d41ae

Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer

Autor: M. Willy Honders, Inge Jedema, Elisabeth H. Slager, Michel G.D. Kester, Roel Willemze, M. Ron Schaafsma, J.H. Frederik Falkenburg, Freke M. Kloosterboer, Simone A.P. van Luxemburg-Heijs, W. A. Erik Marijt, Edith D. van der Meijden

Publikováno v: Blood. 107(12)

Characterization of the antigens recognized by tumor-reactive T cells isolated from patients successfully treated with allogeneic HLA-matched hematopoietic stem cell transplantation (SCT) can lead to the identification of clinically relevant target m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d0eaadb871dc6983d48b1f26bb88cd8
https://pubmed.ncbi.nlm.nih.gov/16497972